Oxaliplatin Injection, Solution
Product Images NDC 71288-149

10 FDA label images from Meitheal Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 71288-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Oxa0u 0000 01)

Structural Formula (Oxa0u 0000 01)
Chemical structure of Oxaliplatin showing the platinum (Pt) center bonded to a cyclohexane diamine ligand and oxalate group.*
FDA Label Image

Figure 1 (Oxa0u 0000 02)

Figure 1 (Oxa0u 0000 02)
A Kaplan-Meier survival curve chart depicting disease progression-free survival (DPS) probability over time in months. The graph compares two treatment arms, FOLFOX4 (solid line) and LV5FU2 (dashed line), showing the number of events and patients at risk at various time points. Statistical data including hazard ratio, 95% confidence interval, and stratified logrank test p-value are included within the chart.*
FDA Label Image

Figure 2 (Oxa0u 0000 03)

Figure 2 (Oxa0u 0000 03)
A Kaplan-Meier survival curve graph showing disease-free survival (DFS) probability over months for two treatment arms: FOLFOX4 - DUKES C and LV5FU2 - DUKES C. The graph includes a hazard ratio with 95% confidence interval and a logrank test p-value, indicating statistical comparison between treatments.*
FDA Label Image

Figure 3 (Oxa0u 0000 04)

Figure 3 (Oxa0u 0000 04)
A Kaplan-Meier survival curve chart comparing median survival of patients treated with Oxaliplatin Injection USP plus 5-FU/LV, Oxaliplatin Injection USP plus Irinotecan, and Irinotecan plus 5-FU/LV over 24 months. The graph plots percent of patients surviving against time in months, showing survival trends and differences among these three treatment regimens.*
FDA Label Image

Premierprorx Logo (Oxa0u 0000 05)

FDA Label Image

Premierprorx Logo (Oxa0u 0000 06)

FDA Label Image

Principal Display Panel (Oxaliplatin Injection, USP 50 mg Vial Label)

Principal Display Panel (Oxaliplatin Injection, USP 50 mg Vial Label)
Label for Oxaliplatin injection, USP 50 mg per 10 mL (5 mg per mL) in a 10 mL single-dose vial. Sterile aqueous solution for intravenous use only. Contains warnings for cytotoxic agent and instructions not to mix with sodium chloride/chloride-containing solutions. Manufactured for Meitheal Pharmaceuticals, Chicago, IL, made in India.*
FDA Label Image

Principal Display Panel (Oxaliplatin Injection, USP 50 mg Carton)

Principal Display Panel (Oxaliplatin Injection, USP 50 mg Carton)
Oxaliplatin 50 mg per 10 mL (5 mg per mL) injection, USP, single-dose vial labeling from Meitheal Pharmaceuticals Inc. The packaging is for intravenous use only and indicates this is a sterile aqueous solution, preservative-free cytotoxic agent. The label warns not to mix or add to sodium chloride or chloride-containing solutions. The carton includes handling and storage information, barcode, and the Premier ProRx branding.*
FDA Label Image

Principal Display Panel (Oxaliplatin Injection, USP 100 mg Vial Label)

Principal Display Panel (Oxaliplatin Injection, USP 100 mg Vial Label)
Label for Oxaliplatin Injection, USP 100 mg per 20 mL (5 mg per mL) single-dose vial by Meitheal Pharmaceuticals Inc. This sterile, preservative-free aqueous solution is for intravenous use only and is labeled as a cytotoxic agent. The label includes storage instructions, barcode, and manufacturer details indicating it is made in India for Premier ProRx.*
FDA Label Image

Principal Display Panel (Oxaliplatin Injection, USP 100 mg Carton)

Principal Display Panel (Oxaliplatin Injection, USP 100 mg Carton)
Carton label for Oxaliplatin Injection, USP 100 mg per 20 mL (5 mg per mL) by Meitheal Pharmaceuticals Inc. The label states it is for intravenous use only and highlights that it is a cytotoxic agent. Warnings include not mixing or adding to sodium chloride or chloride-containing solutions. The carton also provides storage information and notes that the container closure is not made with natural rubber latex.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.